Cell therapy for cardiovascular disease: what cells, what diseases and for whom?
Noel M Caplice*, Bernard J Gersh and Jorge R Alegria
Correspondence
*
Guggenheim 18, Mayo Clinic, 200 First St SW, Rochester, MN
55905, USA
Email Caplice.Noel@mayo.edu
Cells derived from bone marrow, blood, skeletal muscle and other tissues could have regenerative capacity in the human heart and vasculature. Should clinical practice become a reality, however, the indications for which cells, which disease, and which patients are less clear. Noel Caplice and colleagues discuss how such decisions might be made.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
The utility of magnetic resonance imaging in cardiac tissue regeneration trialsNature Clinical Practice Cardiovascular Medicine Article (01 Mar 2006)
Bone-marrow-derived cell transfer after ST-elevation myocardial infarction: lessons from the BOOST trialNature Clinical Practice Cardiovascular Medicine Article (01 Mar 2006)
Bone marrow?derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiationNature Medicine Article (01 May 2004)
The future of cell therapy for acute myocardial infarctionNature Clinical Practice Cardiovascular Medicine Article (01 Mar 2006)
See all 23 matches for Research